David Fitz-patrick, M.D.
Specialist
1585 Kapiolani Blvd, Suite 1500
Honolulu, HI 96814
Who else practices at this address →
Honolulu County includes primary care (9% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 52
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 185
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
HI license MD-4149
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- David Fitz-Patrick, MD Inc. (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 185
- Services billed
- 542
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 664 | 283 |
| Insertion of needle into vein for collection of blood sample | 239 | 166 |
| Hemoglobin a1c level | 183 | 98 |
| Blood test, lipids (cholesterol and triglycerides) | 108 | 79 |
| Injection of drug or substance under skin or into muscle | 101 | 27 |
| Established patient office or other outpatient visit, 20-29 minutes | 85 | 66 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 50 | 23 |
| Blood glucose (sugar) test performed by hand-held instrument | 41 | 35 |
| New patient office or other outpatient visit, 60-74 minutes | 19 | 19 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Honolulu, HI | 244 |
| Atorvastatin Calcium Other prescribers in Honolulu, HI | 160 |
| Ozempic (semaglutide) Other prescribers in Honolulu, HI | 153 |
| Metformin Hcl Other prescribers in Honolulu, HI | 103 |
| Synthroid (levothyroxine sodium) Other prescribers in Honolulu, HI | 92 |
| Jardiance (empagliflozin) Other prescribers in Honolulu, HI | 45 |
| Prolia (denosumab) Other prescribers in Honolulu, HI | 45 |
| Metformin Hcl Er (metformin hcl) Other prescribers in Honolulu, HI | 38 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Honolulu, HI | 37 |
| Nano 2nd Gen Pen Needle (pen needle, diabetic) Other prescribers in Honolulu, HI | 29 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 21 industry-funded studies in 2025, from 10 companies. The companies reported $1,772,457 in research payments for these studies, mostly to the institutions running them.
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06299098 - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are…
Amgen Inc. - A phase 3 protocol to investigate the safety tolerability and immunogenicity of BNT162B2 rnabased variantadapted vaccine candidates against SARSCOV2 in participants 12 through 64 years of age considered at higher risk…
Pfizer Inc. - A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ModernaTX, Inc. · Completed · NCT05127434 - A phase 12 randomized doubleblinded study to evaluate the safety tolerability and immunogenicity of modified rna vaccine candidates against influenza and COVID19 in healthy individuals
Pfizer Inc. - A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Me…
Amgen Inc. - A phase 12 randomized observerblinded study to evaluate the safety tolerability and immunogenicity of combined vaccine candidates against influenza and COVID19 in healthy individuals
Pfizer Inc. - A phase 3 randomized doubleblind placebocontrolled clinical study evaluating the safety tolerability immunogenicity and efficacy of a variantadapted BNT162B2 vaccine in healthy participants 50 through 64 years of age
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.